Company intelligence / Profile preview
Cardurion Pharmaceuticals
Burlington, Massachusetts, USAcardurion.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Cardurion has presented positive clinical data from CARDINAL-HF, the first Phase 2 proof-of-concept clinical trial of a PDE9 inhibitor in patients with heart failure. Based on these results, the company has launched two Phase 2 clinical trials in 640 patients, including a dose-ranging trial in patients with HFrEF and a proof-of-concept trial in patients with HFpEF. The company is also conducting a Phase 2 trial for its CaMKII inhibitor in CPVT. Data readouts for these trials are anticipated in 2026.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
foundational partnerships with key strategics
Beyond the preview
Go deeper on Cardurion Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardurion Pharmaceuticals.